Mixed Hyperlipidemia: when insurers say no, reviewers often say yes

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for the computed tomography (CT) scan of the heart without dye with calcium test for evaluation of the enrollee’s chest pain, abnormal electrocardiogram, and mixed hyperlipidemia. Findings: Two physician reviewer found that Use of the calcium score has been supported by the American College of Cardiology (ACC) as a class IIa or IIb category, which states that this testing may be beneficial in asymptomatic individuals with intermediate coronary risk. Other studies such as exercise testing or coronary angiography are recommended in symptomatic individuals. Since this individual was having chest pain and abnormal EKG with right bundle branch block pattern and past history of syncope, the contrast CT coronary angiogram was indicated, but calcium scoring is not recommended in symptomatic patients.

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. The U.S. Food and Drug Administration (FDA) approved Zepbound for weight management in patients with obesity and at least one comorbidity related to being obese. In addition to obesity, this patient has a history of obesity-related comorbidities, including obstructive sleep apnea (OSA) and mixed hyperlipidemia. The medical literature supports the use of Zepbound for the treatment of obesity, OSA, and mixed hyperlipidemia in conjunction with dietary and lifestyle changes. Moreover, on 12/20/24, the FDA approved Zepbound for the treatment of moderate to severe OSA in adults with obesity. In this case, the patient has a history of obesity and OSA.

Where the denial was upheld

Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for advanced lipoprotein testing. Findings: The physician reviewer found that the records provided for review document that this patient has a family history of coronary artery disease and diagnoses of mixed hyperlipidemia, low high-density lipoprotein (HDL) cholesterol, mild obstructive sleep apnea (OSA), low serum vitamin D, elevated liver enzymes, and essential hypertension. The patient underwent evaluation with advanced lipoprotein testing. In this circumstance, guidelines for the management of cardiac risk established by the American College of Cardiology (ACC) and American Heart Association (AHA) do not support routine advanced lipoprotein testing (Stone, et al.).

Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for cardiac computed tomography (CT) with calcium scoring. Based on the records provided for review, this patient presents with significantly increased coronary risk including mixed hyperlipidemia, abnormal serum protein electrophoresis test results, atypical chest pain, and prediabetes. In this circumstance, the clinical guidelines do not recommend routine performance of specialized tests in the context of assessing coronary risk including coronary calcium quantification, cardiac CT scanning, advanced lipoprotein analysis, genetic testing, and homocysteine.

These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for mixed hyperlipidemia was denied, the published record says the denial is worth fighting.